Next Article in Journal
Implication of Heat Shock Factors in Tumorigenesis: Therapeutical Potential
Next Article in Special Issue
The Role of the Leukemia Inhibitory Factor (LIF) — Pathway in Derivation and Maintenance of Murine Pluripotent Stem Cells
Previous Article in Journal
Genetic Alterations in Glioma
Previous Article in Special Issue
Drug Treatment of Cancer Cell Lines: A Way to Select for Cancer Stem Cells?
Cancers 2011, 3(1), 1141-1157; doi:10.3390/cancers3011141
Review

Retrotransposon-Encoded Reverse Transcriptase in the Genesis, Progression and Cellular Plasticity of Human Cancer

1
, 1
 and 2,*
Received: 11 January 2011; in revised form: 21 February 2011 / Accepted: 22 February 2011 / Published: 7 March 2011
(This article belongs to the Special Issue Cancer Stem Cells)
View Full-Text   |   Download PDF [229 KB, uploaded 7 March 2011]
Abstract: LINE-1 (Long Interspersed Nuclear Elements) and HERVs (Human Endogenous Retroviruses) are two families of autonomously replicating retrotransposons that together account for about 28% of the human genome. Genes harbored within LINE-1 and HERV retrotransposons, particularly those encoding the reverse transcriptase (RT) enzyme, are generally expressed at low levels in differentiated cells, but their expression is upregulated in transformed cells and embryonic tissues. Here we discuss a recently discovered RT-dependent mechanism that operates in tumorigenesis and reversibly modulates phenotypic and functional variations associated with tumor progression. Downregulation of active LINE-1 elements drastically reduces the tumorigenic potential of cancer cells, paralleled by reduced proliferation and increased differentiation. Pharmacological RT inhibitors (e.g., nevirapine and efavirenz) exert similar effects on tumorigenic cell lines, both in culture and in animal models. The HERV-K family play a distinct complementary role in stress-dependent transition of melanoma cells from an adherent, non-aggressive, to a non-adherent, highly malignant, growth phenotype. In synthesis, the retrotransposon-encoded RT is increasingly emerging as a key regulator of tumor progression and a promising target in a novel anti-cancer therapy.
Keywords: tumorigenesis; endogenous reverse transcriptase; reverse transcriptase inhibitors; early embryonic development tumorigenesis; endogenous reverse transcriptase; reverse transcriptase inhibitors; early embryonic development
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Sinibaldi-Vallebona, P.; Matteucci, C.; Spadafora, C. Retrotransposon-Encoded Reverse Transcriptase in the Genesis, Progression and Cellular Plasticity of Human Cancer. Cancers 2011, 3, 1141-1157.

AMA Style

Sinibaldi-Vallebona P, Matteucci C, Spadafora C. Retrotransposon-Encoded Reverse Transcriptase in the Genesis, Progression and Cellular Plasticity of Human Cancer. Cancers. 2011; 3(1):1141-1157.

Chicago/Turabian Style

Sinibaldi-Vallebona, Paola; Matteucci, Claudia; Spadafora, Corrado. 2011. "Retrotransposon-Encoded Reverse Transcriptase in the Genesis, Progression and Cellular Plasticity of Human Cancer." Cancers 3, no. 1: 1141-1157.


Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert